Added to YB: 2026-06-02
Pitch date: 2026-05-29
GSK [neutral]
GSK plc
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 75.1B
Pitch Price
N/A
Price Target
N/A
Dividend
3.83%
EV/EBITDA
7.76
P/E
13.25
EV/Sales
2.76
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 29/5/2026 - GSK – Pipeline progress
GSK (quick overview): Phase III bepirovirsen data shows 19% functional cure rate for chronic hep B vs 0% standard of care—'unprecedented,' potential to redefine treatment. 240M+ live with chronic hep B = clear commercial upside. Cheap at 9.8x 2027 consensus EPS, 3.9% yield.
Read full article (1 min)